Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells.

Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, Gao AC.

Am J Clin Exp Urol. 2019 Aug 15;7(4):203-214. eCollection 2019.

2.

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.

Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D'Abronzo LS, Evans CP, Gao AC.

Mol Cancer Ther. 2019 Oct;18(10):1875-1886. doi: 10.1158/1535-7163.MCT-18-1322. Epub 2019 Jul 15.

PMID:
31308078
3.

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC.

Transl Oncol. 2019 Jul;12(7):871-878. doi: 10.1016/j.tranon.2019.04.007. Epub 2019 May 7.

4.

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.

Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC.

Nat Commun. 2018 Nov 16;9(1):4700. doi: 10.1038/s41467-018-07178-x.

5.

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.

Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M.

Oncotarget. 2018 Oct 2;9(77):34567-34581. doi: 10.18632/oncotarget.26179. eCollection 2018 Oct 2.

6.

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.

Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2018 Oct;17(10):2197-2205. doi: 10.1158/1535-7163.MCT-17-1269. Epub 2018 Jun 11.

7.

ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.

Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Oct;16(10):2257-2266. doi: 10.1158/1535-7163.MCT-17-0179. Epub 2017 Jul 11.

8.

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.

Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.

Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.

9.

MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC.

Prostate. 2017 Jun;77(9):1020-1028. doi: 10.1002/pros.23358.

10.

The emerging role of the androgen receptor in bladder cancer.

Lombard AP, Mudryj M.

Endocr Relat Cancer. 2015 Oct;22(5):R265-77. doi: 10.1530/ERC-15-0209. Epub 2015 Jul 30. Review.

PMID:
26229034
11.

Dicer ablation promotes a mesenchymal and invasive phenotype in bladder cancer cells.

Lombard AP, Lim RM, Nakagawa RM, Vidallo KD, Libertini SJ, Platero AJ, Mudryj M.

Oncol Rep. 2015 Sep;34(3):1526-32. doi: 10.3892/or.2015.4117. Epub 2015 Jul 9.

PMID:
26166215
12.

miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1.

Lombard AP, Mooso BA, Libertini SJ, Lim RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM, Mudryj M.

Mol Carcinog. 2016 May;55(5):757-67. doi: 10.1002/mc.22319. Epub 2015 Apr 11.

Supplemental Content

Loading ...
Support Center